BACKGROUND: Bariatric surgery is the most effective long-term treatment for morbid obesity, reducing obesity-associated comorbidities. The purpose of the present study was to evaluate the UCP3 promotor (-55C-->T) polymorphism outcomes 1 year after biliopancreatic diversion in morbidly obese patients. METHODS: A sample of 40 morbidly obese patients (BMI >40 kg/m(2)) were operated. Weight, fat mass, blood pressure, basal glucose, triacylglycerols, total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were measured at basal visit and at each visit. The frequency of patients with diabetes mellitus, hypertension, and hyperlipidemia was recorded at each visit. RESULTS: Twenty-eight patients (70%) had the genotype C/C (wild group) and 12 (30%) patients C/T (mutant group). In wild type group, body mass index, weight, fat mass, systolic blood pressure, glucose, total cholesterol, low-density lipoprotein cholesterol, and triacylglycerols concentrations decreased. In mutant type group, the same parameters improved, without statistical differences with wild group. Initial weight percent loss at 1 year of follow-up was similar in both genotypes (34.1% vs 28.6%; ns). CONCLUSION: Polymorphism -55C/T of the UCP3 promotor did not have an effect on weight loss or clinical outcomes after bariatric surgery.
BACKGROUND: Bariatric surgery is the most effective long-term treatment for morbid obesity, reducing obesity-associated comorbidities. The purpose of the present study was to evaluate the UCP3 promotor (-55C-->T) polymorphism outcomes 1 year after biliopancreatic diversion in morbidly obesepatients. METHODS: A sample of 40 morbidly obesepatients (BMI >40 kg/m(2)) were operated. Weight, fat mass, blood pressure, basal glucose, triacylglycerols, total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were measured at basal visit and at each visit. The frequency of patients with diabetes mellitus, hypertension, and hyperlipidemia was recorded at each visit. RESULTS: Twenty-eight patients (70%) had the genotype C/C (wild group) and 12 (30%) patients C/T (mutant group). In wild type group, body mass index, weight, fat mass, systolic blood pressure, glucose, total cholesterol, low-density lipoprotein cholesterol, and triacylglycerols concentrations decreased. In mutant type group, the same parameters improved, without statistical differences with wild group. Initial weight percent loss at 1 year of follow-up was similar in both genotypes (34.1% vs 28.6%; ns). CONCLUSION: Polymorphism -55C/T of the UCP3 promotor did not have an effect on weight loss or clinical outcomes after bariatric surgery.
Authors: J C Clapham; J R Arch; H Chapman; A Haynes; C Lister; G B Moore; V Piercy; S A Carter; I Lehner; S A Smith; L J Beeley; R J Godden; N Herrity; M Skehel; K K Changani; P D Hockings; D G Reid; S M Squires; J Hatcher; B Trail; J Latcham; S Rastan; A J Harper; S Cadenas; J A Buckingham; M D Brand; A Abuin Journal: Nature Date: 2000-07-27 Impact factor: 49.962
Authors: L T Dalgaard; T I Sørensen; T Drivsholm; K Borch-Johnsen; T Andersen; T Hansen; O Pedersen Journal: J Clin Endocrinol Metab Date: 2001-03 Impact factor: 5.958
Authors: Alvaro Alonso; Amelia Martí; María Soledad Corbalán; Miguel A Martínez-González; Luis Forga; J Alfredo Martínez Journal: Ann Nutr Metab Date: 2005-07-07 Impact factor: 3.374
Authors: N Scopinaro; G F Adami; G M Marinari; E Gianetta; E Traverso; D Friedman; G Camerini; G Baschieri; A Simonelli Journal: World J Surg Date: 1998-09 Impact factor: 3.352
Authors: Daniel Antonio de Luis; Rocio Aller; Olatz Izaola; Manuel Gonzalez Sagrado; Rosa Conde; David Primo; Beatriz de la Fuente; Hilda F Ovalle; Marta Ruiz Mambrilla Journal: J Clin Lab Anal Date: 2012-07 Impact factor: 2.352